<DOC>
<DOCNO>EP-0623168</DOCNO> 
<TEXT>
<INVENTION-TITLE>
T CELL EPITOPES OF THE MAJOR ALLERGENS FROM DERMATOPHAGOIDES (HOUSE DUST MITE).
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3800	A61K3800	A61K3935	A61K3935	A61P3700	A61P3708	C07K14435	C07K14435	C07K14725	C12N1509	C12N1509	C12N1512	C12N1512	C12N1562	C12N1562	C12P2102	C12P2102	C12Q102	C12Q102	C12R119	G01N3353	G01N3353	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61P	A61P	C07K	C07K	C07K	C12N	C12N	C12N	C12N	C12N	C12N	C12P	C12P	C12Q	C12Q	C12R	G01N	G01N	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K38	A61K38	A61K39	A61K39	A61P37	A61P37	C07K14	C07K14	C07K14	C12N15	C12N15	C12N15	C12N15	C12N15	C12N15	C12P21	C12P21	C12Q1	C12Q1	C12R1	G01N33	G01N33	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The present invention provides isolated peptides of the major protein allergens of the genus Dermatophagoides. Peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen selected from the allergens Der p I, Der p II, Der f I, or Der f II. The invention also pertains to modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having reduced side effects. The invention further provides nucleic acid sequences coding for peptides of the invention. Methods of treatment or of diagnosis of sensitivity to house dust mites in an individual and therapeutic compositions comprising one or more peptides of the invention are also provided.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
IMMULOGIC PHARMA CORP
</APPLICANT-NAME>
<APPLICANT-NAME>
IMMULOGIC PHARMACEUTICAL CORPORATION
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
GARMAN RICHARD D
</INVENTOR-NAME>
<INVENTOR-NAME>
GREENSTEIN JULIA L
</INVENTOR-NAME>
<INVENTOR-NAME>
KUO MEI-CHANG
</INVENTOR-NAME>
<INVENTOR-NAME>
ROGERS BRUCE L
</INVENTOR-NAME>
<INVENTOR-NAME>
GARMAN, RICHARD, D.
</INVENTOR-NAME>
<INVENTOR-NAME>
GREENSTEIN, JULIA, L.
</INVENTOR-NAME>
<INVENTOR-NAME>
KUO, MEI-CHANG
</INVENTOR-NAME>
<INVENTOR-NAME>
ROGERS, BRUCE, L.
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
 T CELL EPITOPES OF THE MAJOR ALLERGENS FROM DERMATOPHAGOIDES (HOUSE DUST MITE)Related ApplicationsThis application is a continuation-in-part of U.S.S.N. 07/881,396 entitled "T Cell Epitopes of the Major Allergens From Dermatophagoides (House Dust Mite), filed May 8, 1992, which is a continuation-in-part of U.S.S.N. 07/777,859 entitled "T Cell Epitopes of the Major Allergens From Dermatophagoides (House Dust Mite)", filed October 16, 1991, the teachings of which are incorporated herein by reference.Background of the InventionRecent reports have documented the importance of responses to the Group I (e.g., Der p I and Der f I) and Group II (e.g., Der p π and Der f II) protein allergens in house dust mite allergy. For example, it has been documented that over 60% of patients have at least 50% of their anti-mite antibodies directed towards these proteins (e.g., Lind, P. et al., Allergy. 22:259-274 (1984); van der Zee, IS. et al., Journal Allergy and Clinical Immunology. £1:884-896 (1988)). It is possible that children show a greater degree of reactivity to the Group I and Group II allergens (Thompson, P. J., et al., Immunology. :301-314 (1988)). Allergy to mites of the genus Dermatophagoides (D.) is associated with conditions such as asthma, rhinitis and ectopic dermatitis. Two species, _Q_, pteronyssinus and E farinae. predominate and, as a result, considerable effort has been expended in trying to identify the allergens produced by these two species.A concerted effort has been made to characterize by gene cloning* the major allergens from both D,. pteronyssinus and Jλ farinae. Consequently, ft several publications have reported the complete nucleotide sequences of\ several allergens including Der p I (Thomas, W.R., et al., InternationalArchives of Allergy and Applied Immunology. 85:127-129 (1988); and Chua, K.Y., et al., Journal of Experimental Medicine. 1^2:175-182 (1988)), Der p II (Chua, K.Y., et al., International Archives of Allergy and Applied Immunology. 91:118-123 (1990)), Dgr f I (Dilworth, R.J., et al. Clinical and Experimental Allergy 21 :25-32 (1891V.. Dgr f II (Yuu i, T., et al., Japan 

 Joumal Allergol.. 29:557-461 (1990); and Trudinger, M., et al.- Clinical and Experimental Allergy. 21:33-37 (1991)) and a low molecular weight allergen (Ovey, E.R., et al., Journal of Experimental Medicine. JJQ: 1457-1462 (1989)). The published nucleotide sequences of cDNAs encoding Der p I and Der f I demonstrate that these two proteins are highly homologous at the amino acid level (81% identity) and that
</DESCRIPTION>
<CLAIMS>
Claims
1. An isolated peptide of a protein allergen of the genus Dermatophagoides. said peptide comprising at least one T cell epitope of said protein allergen, said peptide having a positivity index of at least about 150 and mean T cell stimulation index of at least about 4.0 determined in a population of individuals sensitive to said protein allergen.
2. An isolated peptide of claim 1 selected from the group consisting of: DP I-l (SEQ ID NO: 9); DP 1-21.1 (SEQ ID NO: 27); DP 1-21.2 (SEQ ID NO: 28); DP 1-23.1 (SEQ ID NO: 33); DP 1-23.2 (SEQ ID NO: 34); DP I- 25.2 (SEQ ID NO: 36); and DP 1-26.1 (SEQ ID NO: 37).
3. An isolated peptide of claim 1 selected from d e group consisting of DP 1-21.2, DP 123.1, DP 126.1, DP E-20.6, DP 11-22, DPE-25.2 and DF 1-22.2 as shown in Figs.3 and 4.
4. An isolated peptide of claim 1 which does not bind immunoglobulin E specific for a protein allergen of the genus Dermatophagoides in a substantial percentage of individuals sensitive to the protein allergen, or if binding of d e peptide to said immunoglobulin E occurs, such binding does not result in release of mediators from mast cells or basophils in a substantial percentage of individuals sensitive to the protein allergen.
5. An isolated peptide of claim 1 which binds immunoglobulin E to a substantially lesser extent than the protein allergen from which the peptide is derived binds said immunoglobulin E.
6. An isolated peptide of claim 2 wherein the population of individuals is at least 9 individuals.
7. An isolated peptide of claim 2 wherein the population of individuals is at least 29 individuals.
8. An isolated peptide of claim 1 which comprises at least two T cell epitopes. 


9. An isolated peptide of claim 1 which, when administered to an individual sensitive to house dust mite, induces T cell anergy in the individual or modifies d e lymphokine secretion profile of T cells in the individual.
10. All or a portion of an isolated peptide of Der p I comprising at least one T cell epitope of Der p I. said peptide selected from the group consisting of: a) DP I-l (SEQ ID NO: 9); b) DP 1-2 (SEQ ID NO: 10); c) DP 1-3 (SEQ ID NO: 11); d) DP 1-4 (SEQ ID NO: 12); e) DP I- 11.1 (SEQ ID NO: 13); f) DP I-12.1 (SEQ ID NO: 14); g) DP 1-5 (SEQ ID NO: 15); h) DP 1-13 (SEQ ID NO: 17); i) DP 1-14 (SEQ ID NO: 18); j) DP 1-15 (SEQ ID NO: 19); k) DP 1-6.1 (SEQ ID NO: 20); 1) DP 1-7.1 (SEQ ID NO: 21); m) DP 1-8 (SEQ ID NO: 22); n) DP 1-9 (SEQ ID NO: 23); o) DP 1-16 (SEQ ID NO: 24); p) DP 1-10 (SEQ ID NO: 25); q) DP 1-17 (SEQ ID NO: 26); r) DP 1-21.1 (SEQ ID NO: 27); s) DP 1-21.2 (SEQ ID NO: 28); t) DP 1-22.1 (SEQ ID NO: 29); u) DP 1-22.2 (SEQ ID NO: 30); v) DP 1-22.3 (SEQ ID NO: 31); w) DP 1-22.4 (SEQ ID NO: 32) ; x) DP 1-23.1 (SEQ ID NO: 33); y) DP 1-23.2 (SEQ D NO: 34); z) DP 1-25.1 (SEQ D NO: 35); a') DP 1-25.2 (SEQ E) NO: 36); b") DP 1-26.1 (SEQ ID NO: 37); c') DP 1-27.1 (SEQ ID NO: 38); 


 d') DP 1-28.1 (SEQ E
>
 NO: 39); and e
*
) DP 1-28.2 (SEQ ID NO: 40), wherein said portion of said peptide has a mean T cell stimulation index equivalent to, or greater than the mean T cell stimulation index of said peptide as shown in Fig. 5 and Fig. 13.
11. A portion of an isolated peptide of claim 10 which has a mean T ceE stimulation index of at least 4.0.
12. All or a portion of an isolated peptide of claim 10 which does not bind immunoglobulin E specific for Der p I in a substantial percentage of individuals sensitive to Der p I, or if binding of die peptide or portion ti ereof to said immunoglobulin E occurs, such binding does not result in release of mediators from mast cells or basophils in a substantial percentage of individuals sensitive to Der p I.
13. All or a portion of an isolated peptide of claim 10 which modifies, in an individual sensitive to house dust mite to whom it is administered, me allergic response of the individual to a house dust mite allergen.
14. A portion of an isolated peptide of claim 10 wherein the portion comprises at least 15 amino acid residues.
15. An isolated nucleic acid having a sequence encoding all or a portion of a peptide of claim 10, or the functional equivalent of said nucleic acid sequence.
16. An isolated peptide which is immunologically cross-reactive witii antibodies specific for all or a portion of a peptide of claim 10.
17. An isolated peptide which is immunologically cross-reactive witii T cells reactive with all or a portion of a peptide of claim 10.
18. An isolated peptide of Der p i having an amino acid sequence substantially corresponding to an amino acid sequence of a peptide selected from the group consisting of: a) DP 1-1 (SEQ ID NO: 9); 


 b) DP 1-2 (SEQ ID NO: 10) c) DP 1-3 (SEQ ID NO: 11) d) DP 1-4 (SEQ ID NO: 12) e) DP I-l l.l (SEQ ID NO: 13); f) DP 1-12.1 (SEQ ID NO: 14); g) DP 1-5 (SEQ ID NO: 15); h) DP 1-13 (SEQ ID NO: 17) i) DP 1-14 (SEQ ID NO: 18) j) DP 1-15 (SEQ ID NO: 19) k) DP 1-6.1 (SEQ ID NO: 20); 1) DP 1-7.1 (SEQ ID NO: 21); m) DP 1-8 (SEQ ID NO: 22); n) DP 1-9 (SEQ ID NO: 23); o) DP 1-16 (SEQ ID NO: 24) p) DP 1-10 (SEQ E
>
 NO: 25) q) DP 1-17 (SEQ ID NO: 26) r) DP 1-21.1 (SEQ ID NO: 27) s) DP 1-21.2 (SEQ ID NO: 28) t) DP 1-22.1 (SEQ ID NO: 29) u) DP 1-22.2 (SEQ ID NO: 30) v) DP 1-22.3 (SEQ ID NO: 31) w) DP 1-22.4 (SEQ ID NO: 32) x) DP 1-23.1 (SEQ ID NO: 33) y) DP 1-23.2 (SEQ ID NO: 34) z) DP 1-25.1 (SEQ ID NO: 35) a') DP 1-25.2 (SEQ ID NO: 36) b') DP 1-26.1 (SEQ ID NO: 37) c") DP 1-27.1 (SEQ ID NO: 38) d') DP 1-28.1 (SEQ ID NO: 39) e') DP 1-28.2 (SEQ ID NO: 40) and f) DP I-5.1 (SEQ ID NO: 16).
19. An isolated nucleic acid having a sequence encoding a peptide of claim 18, or the functional equivalent of said nucleic acid sequence. 


 and 

21. A modified peptide or a modified portion of a peptide of claim 10.
22. A modified peptide of claim 18.
23. A modified peptide of claim 18 selected from the group of peptides consisting of DP 1-23.1.1, DPI-23.1.2, DP 1-23.1.3, and DP 1-23.1.4 as shown in Fig. 28.
24. A modified peptide or a modified portion of a peptide of claim 21 which does not bind immunoglobulin E specific for Der p I in a substantial percentage of individuals sensitive to Derp I, or if binding of d e peptide or portion thereof to said immunoglobulin E occurs, such binding does not result in release of mediators from mast cells or basophils in a substantial percentage of individuals sensitive to Derp I.
25. A modified peptide or a modified portion of a peptide of claim 21 which modifies, in an individual sensitive to house dust mite to whom it is 


administered, the allergic response of the individual to a house dust mite allergen.
26. An isolated peptide comprising at least two regions, each region comprising at least one T cell epitope of a protein allergen of the genus Dermatophagoides. said regions derived from the same or from different protein allergens of d e genus Dermatophagoide
S, said regions each comprising all or a portion of an amino acid sequence selected from the group consisting of: a) DP 1-21.1 (SEQ ID NO: 27); b) DP 1-21.2 (SEQ ID NO: 28); c) DP 1-22.1 (SEQ ID NO: 29); d) DP 1-22.2 (SEQ ID NO: 30); e) DP 1-22.3 (SEQ ID NO: 31); f) DP 1-22.4 (SEQ ID NO: 32); g) DP 1-23.1 (SEQ E
>
 NO: 33); h) DP 1-23.2 (SEQ ID NO: 34); i) DP 1-25.1 (SEQ ID NO: 35); j) DP 1-25.2 (SEQ ID NO: 36); k) DP 1-26.1 (SEQ ID NO: 37); 1) DP 1-27.1 (SEQ ID NO: 38); m) DP 1-28.1 (SEQ ID NO: 39); n) DP 1-28.2 (SEQ ID NO: 40); o) DP I-l (SEQ ID NO: 9); p) DF I-l (SEQ ID NO: 72); q) DF 1-21.1 (SEQ ID NO: 90); r) DF 1-21.2 (SEQ ID NO: 91); s) DF 1-22.1 (SEQ ID NO: 92); t) DF 1-22.2 (SEQ ID NO: 93); u) DF 1-22.4 (SEQ ID NO: 94); v) DF 1-23.1 (SEQ ID NO: 95); w) DF 1-23.2 (SEQ ID NO: 96); x) DF 1-25.1 (SEQ ID NO: 97); y) DF 1-25.2 (SEQ ID NO: 98); z) DF 1-26.1 (SEQ ID NO: 99); a') DF 1-27.1 (SEQ ID NO: 100); b') DF 1-28.1 (SEQ ID NO: 101); 


 -96-
c") DF 1-28.2 (SEQ ID NO: 102): d') DP E-20 (SEQ ID NO: 50); e') DP E-20.1 (SEQ ID NO: 51); f ) DP E-20.2 (SEQ ID NO: 52); g") DP E-20.3 (SEQ ID NO: 53); h') DP E-20.4 (SEQ D NO: 54); i') DP E-20.5 (SEQ ED NO: 55); j') DP E 20.6 (SEQ TD NO: 56); k') DP E-l (SEQ ED NO: 41);
D DP E-l.l (SEQ ED NO: 57); m') DP E-1.2 (SEQ ED NO: 58); n') DP E-2.1 (SEQ ED NO: 59); o') DP E-2.2 (SEQ ED NO: 60); p') DP E-2.3 (SEQ ED NO: 61); q') DP E-21 (SEQ ED NO: 62); r') DP E-22 (SEQ ED NO: 63); s') DP E-26 (SEQ ED NO: 64); t') DP E-26.1 (SEQ ED NO: 65); u') DP E-23 (SEQ ED NO: 66); v') DP E-23.1 (SEQ ED NO: 67); w") DP E-24 (SEQ ED NO: 68); x*) DP E-25 (SEQ ED NO: 69); y') DP E-25.1 (SEQ ED NO: 70); z') DP E-25.2 (SEQ ED NO: 71); a") DF E-l (SEQ ED NO: 103) b") DF E-2 (SEQ ED NO: 104); c") DF E-13.1 (SEQ ED NO: 105); d") DF E-3.1 (SEQ ED NO: 106); e") DF E-4.5 (SEQ ED NO: 107); f ') DF E-4.3 (SEQ ED NO: 108); g") DF E- 15 (SEQ ED NO: 109); h") DF E-16 (SEQ ED NO: 110); i") DF E-17 (SEQ ED NO: 111); j") DF E-18 (SEQ TD NO: 112); k") DF E-19 (SEQ ED NO: 113);
1") DF E-19.1 (SEQ ED NO: 114); m") DF E-21 (SEQ ED NO: 115); and 


 n") DF E-22 (SEQ ID NO: 116).
27. An isolated peptide of claim 26 wherein said regions comprise an amino acid sequence selected from the group consisting of: a) DP 1-21.1 (SEQ ID NO: 27); b) DP 1-21.2 (SEQ ID NO: 28); c) DP 1-22.1 (SEQ ID NO: 29); d) DP 1-23.1 (SEQ ID NO: 33); e) DP 1-25.2 (SEQ ID NO: 36); f) DP 1-26.1 (SEQ ID NO: 37); g) DP 1-28.1 (SEQ ID NO: 39); h) DP I-l (SEQ ID NO: 9); i) DF I-l (SEQ ID NO: 72); j) DF 1-21.1 (SEQ ID NO: 90); k) DF 1-22.1 (SEQ ED NO: 92);
1) DF 1-23.1 (SEQ ED NO: 95); m) DF 1-25.1 (SEQ ED NO: 97); n) DP E-l (SEQ ED NO: 41); o) DP -1.2 (SEQ ED NO: 58); p) DP E-2.0 (SEQ ID NO: 56); q) DP II-20.3 (SEQ ID NO: 53); r) DP E-21 (SEQ ED NO: 62); s) DP E-22 (SEQ ED NO: 63); t) DP E-25 (SEQ ID NO: 69); u) DP E-25.2 (SEQ ID NO: 71); v) DF E-2 (SEQ ED NO: 104); w) DF E-4.5 (SEQ ED NO: 107); x) DF E-15 (SEQ ED NO: 109); y) DF II-17 (SEQ ID NO: lll); z) DF E-19.1 (SEQ ID NO: 114) a') DFI-22.2 (SEQ ID NO:93); and b') DP E-20.6 (SEQ ID NO:56).
28. An isolated peptide of claim 26 wherein said regions comprise all or a portion of an amino acid sequence selected from the group consisting of: a)DP 1-21.2 (SEQ ID NO:27); b)DP 1-23.1 (SEQ ED NO.33); 


 c)DP 1-26.1 (SEQ ED NO:37); d)DP E-20.6(SEQ ED NO:56); e)DP E-22 (SEQ ED NO:63); f)DP E-25.2 (SEQ ED NO:71); and g)DF 1-22.2 (SEQ ED NO:93). all as shown in Figs. 3 and 4.
29. An isolated peptide of claim 26 wherein said regions comprise an amino acid sequence selected from the group consisting of: a)DP 1-21.2 (SEQ ID NO:27); b)DP 1-23.1 (SEQ D NO:33); c)DP 1-26.1 (SEQ ED NO:37); d)DP E-20.6(SEQ ID NO:56); e)DP E-22 (SEQ ED NO:63); f)DP E-25.2 (SEQ ED NO:71); and g)DF 1-22.2 (SEQ ED NO:93), all as shown in Figs. 3 and 4.
30. An isolated peptide of claim 26, wherein said peptide comprises a combination of regions selected from the group consisting of: a) DP 1-22.1 (SEQ TD NO: 29) and DP 1-25.1 (SEQ ED NO: 35); b) DP 1-21.1 (SEQ ED NO: 27) and DP 1-25.2 (SEQED NO: 36); c) DP 1-22.1 (SEQ ID NO: 29) and DP I-l (SEQ ED NO: 9); d) DP 1-21.1 (SEQ ED NO: 27), DP 1-22.1 (SEQ ED NO: 29), and DP 1-25.2 (SEQ ED NO: 36); e) DP 1-21.2 (SEQ ED NO: 28), DP 1-22.1 (SEQ ED NO: 29), and DP 1-23.1 (SEQ ID NO: 39); f) DP I-l (SEQ TD NO: 9), DP 1-22.1 (SEQ ED NO: 29), and DP 1-23.1 (SEQ ED NO: 33); g) DP I-l (SEQ ED NO: 9), DP 1-22.1 (SEQ ID NO: 29), and DP 1-25.2 (SEQ ED NO: 36); h) DP I-2I.1 (SEQ D NO: 27), DP 1-22.1 


 (SEQ ID NO: 29), DP 1-23.1 (SEQ ID NO:
33), and DP 1-25.2 (SEQ ID NO: 36); i) DP 1-21.2 (SEQ D NO: 28), DP 1-22.1
(SEQ ID NO: 29), and DP 1-25.2 (SEQ ID
NO: 36); j) DP 1-21.2 (SEQ D NO: 27), DP 1-22.1
(SEQ ID NO: 29), DP 1-25.2 (SEQ ID NO:
36), and DP 1-26.1 (SEQ ID NO: 37); k) DF 1-21.2 (SEQ ID NO: 91) and DF 1-22.1
(SEQ ID NO: 92);
1) DF 1-21.1 (SEQ D NO: 90), DF 1-22.1
(SEQ ID NO: 92), and DF 1-25.1 (SEQ ID
NO: 97); m) DF 1-21.2 (SEQ ED NO: 91 ), DF 1-22.1
(SEQ ID NO: 92), and DF 1-25.1 (SEQ ID
NO: 97); n) DF I- 1 (SEQ ID NO: 72) and DF 1-22.1
(SEQ ID NO: 92); o) DF I- 1 (SEQ ED NO: 72), DF 1-22.1 (SEQ
ID NO: 92), and DF 1-25.1 (SEQ ID NO: 97); p) DF 1-22.1 (SEQ ID NO: 29), and DF 1-25.1
(SEQ ID NO: 35); q) DF 1-21.1 (SEQ ED NO: 90), DF 1-22.1
(SEQ ED NO: 92), and DF 1-23.1 (SEQ ID
NO: 95); r) DP 1-21.1 (SEQ ED NO: 27), and DF 1-22.1
(SEQ ED NO: 92); s) DP I-l (SEQ ED NO: 9), DP 1-23.1 (SEQ ED
NO: 33), DP 1-25.1 (SEQ ID NO: 35), and
DF I-l (SEQ ID NO: 72); t) DP I- 1 (SEQ ED NO: 9), DP 1-25.1 (SEQ ED
NO: 35), DP 1-23.1 (SEQ ID NO: 33), and
DF 1-21.2 (SEQ ED NO: 91); u) DP I-l (SEQ ED NO: 9), DP 1-25.1 (SEQ ID
NO: 35), DP 1-23.1 (SEQ ID NO: 33), and
DF 1-21.1 (SEQ ED NO: 90); v) DP E-22 (SEQ ID NO: 63), and DP E-25.2 


 (SEQ ED NO: 71); w) DP E-22 (SEQ ED NO: 63), DP E-25.2
(SEQ ED NO: 71), and DP 1-21.1 (SEQ ID
NO: 27) and DP 1-22.1 (SEQ ED NO: 29); x) DP E-22 (SEQ ED NO: 63), DP E-25.2
(SEQ ED NO: 71), DP E-20.6 (SEQ ED NO:
56), DP 1-22.1 (SEQ ED NO: 29), DP 1-21.1
(SEQ ID NO: 27), and DP 1-23.1 (SEQ ID
NO: 33); y) DP E-22 (SEQ ED NO: 63), DP E-25.2
(SEQ ED NO: 71), DP E-20.6 (SEQ ED NO:
56), DP 1-21.1 (SEQ ED NO: 27), DP 1-22.1
(SEQ ED NO: 29), and DP 1-25.2 (SEQ D
NO: 36); z) DP E-22 (SEQ ED NO: 63), DP E-25.2
(SEQ ED NO: 71), DP 1-21.1 (SEQ ED NO:
27), DP 1-22.1 (SEQ ED NO: 29), and DP I-
25.2 (SEQ ED NO: 36); a') DP E-22 (SEQ ED NO: 63), DP E-25.2
(SEQ ED NO: 71), DP 1-21.1 (SEQ ED NO:
27), DP 1-22.1 (SEQ ED NO: 29), and DP I-
23.1 (SEQED NO: 33); b
"
) DP E-22 (SEQ ED NO; 63), DP E-25.2
(SEQ ED NO: 71), DP I-l (SEQ ED NO: 9), and DP 1-22.1 (SEQ ID NO: 29); c') DF E-4.5 (SEQ ED NO: 107) and DF E-2 (SEQ ED NO: 104); d') DF E-4.5 (SEQ ED NO: 107) and DF E-19.1
(SEQ ED NO: 114); e') DF E-4.5 (SEQ ED NO: 107), DF E-2 (SEQ
ED NO: 104), and DF E-19.1 (SEQ ED NO: 114); f ) DF E-4.5 (SEQ ED NO: 107), DF E-2 (SEQ
ED NO: 104), and DF E-9 (SEQ ED NO: 86); g') DF E-4.5 (SEQ ED NO: 107); and DF 1-21.1
(SEQ ED NO: 90); h') DF E-4.5 (SEQ ED NO: 107), DP E-22
(SEQ ED NO: 63), and DP E-25.2 (SEQ ED 


 NO: 71); and i") DF 11-4.5 (SEQ ID NO: 107), DF E-2 (SEQ
ID NO: 104), and DP E-22 (SEQ ID NO: 63).
31. An isolated peptide of claim 26 wherein said peptide comprises the following combination of regions: DP 1-21.2(SEQ ID NO:27),DP I-
23.1 (SEQ ID NO:33), DP 1-26.1 (SEQ ID NO:37), DP E-20.6(SEQ ID NO:56), DP E-22(SEQ ID NO:63), DP II-25.2(SEQ ID NO:71), and DF I- 22.2(SEQ TD NO:93).
32. An isolated nucleic acid having a sequence encoding all or a portion of a peptide of claim 28, or the functional equivalent of said nucleic acid sequence.
33. An isolated peptide produced in a host cell transformed witii the nucleic acid of claim 32.
34. An isolated peptide of claim 26 wherein said peptide has a specific sequential arrangement of amino acid sequences, said arrangement of amino acid sequences selected from the group consisting of: a) DP 1-26.1, DP E-25.2, DF 1-22, DP E-20.6 and DPI-21.2 respectively as shown in Fig.25; b) DP E-25.2, DF 1-22.2, DP 1-23.1 DP E-22, DP 1-26.1 DPI-21.2 and DP E-20.6 respectively as shown in Fig. 26; and c) DP E-25.2, DP 1-21.1, DP 1-26.1, DP E-22, DP E-20.6 and DF 1-22.2 respectively as shown in Fig. 27.
35. An isolated peptide of claim 26 wherein the regions comprise an amino acid sequence selected from the group consisting of: a) DP 1-21.1 (SEQ ID NO: 27); b) DP 1-21.2 (SEQ ID NO: 28); c) DP 1-22.1 (SEQ ID NO: 29); d) DP 1-22.2 (SEQ ID NO: 30); e) DP 1-22.3 (SEQ ID NO: 31); f) DP 1-22.4 (SEQ ID NO: 32); g) DP 1-23.1 (SEQ ED NO: 33); h) DP 1-23.2 (SEQ ID NO: 34); 


 -102-
i) DP 1-25.1 (SEQ ID NO: 35) j) DP 1-25.2 (SEQ ED NO: 36) k) DP 1-26.1 (SEQ ID NO: 37)
1) DP 1-27.1 (SEQ ED NO: 38) m) DP 1-28.1 (SEQ ED NO: 39) n) DP 1-28.2 (SEQ ED NO: 40) o) DP I-l (SEQ ED NO: 9); p) DFI-l (SEQ ED NO: 72); q) DF 1-21.1 (SEQ ED NO: 90) r) DF 1-21.2 (SEQ ED NO: 91) s) DF 1-22.1 (SEQ ED NO: 92) t) DF 1-22.2 (SEQ ID NO: 93) u) DF 1-22.4 (SEQ ED NO: 94) v) DF 1-23.1 (SEQ ED NO: 95) w) DF 1-23.2 (SEQ ED NO: 96) x) DF 1-25.1 (SEQ ED NO: 97) y) DF 1-25.2 (SEQ ED NO: 98) z) DF 1-26.1 (SEQ ED NO: 99) a') DF 1-27.1 (SEQ ED NO: 100) b
l
) DF 1-28.1 (SEQ ED NO: 101) c') DF 1-28.2 (SEQ ED NO: 102) d') DP E-20 (SEQ ED NO: 50); e') DP E-20.1 (SEQ ED NO: 51) f ) DP E-20.2 (SEQ ED NO: 52) g') DP E-20.3 (SEQ ED NO: 53) h') DP E-20.4 (SEQ ED NO: 54) i') DP E-20.5 (SEQ ED NO: 55) j*) DP E 20.6 (SEQ ED NO: 56) k') DP E-l (SEQ ED NO: 41);
1') DP E-l.l (SEQ DD NO: 57); m') DP -1.2 (SEQ ED NO: 58); n') DP E-2.1 (SEQ ED NO: 59); o') DP E-2.2 (SEQ ED NO: 60); p") DP E-2.3 (SEQ ID NO: 61); q') DP E-21 (SEQ ED NO: 62); r') DP E-22 (SEQ ED NO: 63); s') DP E-26 (SEQ ED NO: 64); 


 t') DP II-26.1 (SEQ ID NO: 65); u') DP 11-23 (SEQ ID NO: 66); v') DP 11-23.1 (SEQ ID NO: 67); w') DP II-24 (SEQ ID NO: 68); x') DP E-25 (SEQ ID NO: 69); y') DP E-25.1 (SEQ ID NO: 70); z') DP E-25.2 (SEQ ID NO: 71); a") DF E-l (SEQ ID NO: 103) b") DF E-2 (SEQ ID NO: 104); c") DF II-13.1 (SEQ ID NO: 105); d") DF II-3.1 (SEQ ID NO: 106); e") DF E-4.5 (SEQ ID NO: 107); f ') DF E-4.3 (SEQ ID NO: 108); g") DF E-15 (SEQ ID NO: 109); h") DF II- 16 (SEQ ED NO: 110); i") DF II- 17 (SEQ ED NO: 111); j") DF E-18 (SEQ ID NO: 112); k") DF E-19 (SEQ ID NO: 113);
1") DF E-19.1 (SEQ ID NO: 114) m") DF E-21 (SEQ ID NO: 115); and n") DF E-22 (SEQ ED NO: 116).
36. An isolated nucleic acid having a sequence encoding all or a portion of a peptide of claim 26, or the functional equivalent of said nucleic acid sequence.
37. An isolated peptide produced in a host cell transformed with the nucleic acid of claim 36.
38. All or a portion of an isolated peptide of a protein allergen of the genus Dermatophagoides. said peptide or portion thereof comprising at least one T cell epitope of said protein allergen, said peptide having the formula Xn-Y-Z
jjj
, wherein Y is an amino acid sequence selected from the group consisting of: a) DF 1-21.1 (SEQ ID NO: 90); b) DF 1-21.2 (SEQ ID NO: 91); c) DF 1-22.1 (SEQ ID NO: 92); 


 d) DF 1-22.2 (SEQ ID NO: 93); e) DF 1-22.4 (SEQ ID NO: 94) f) DF 1-23.1 (SEQ ED NO: 95) g) DF 1-23.2 (SEQ ED NO: 96) h) DF 1-25.1 (SEQ ED NO: 97) i) DF 1-25.2 (SEQ ED NO: 98) j) DF 1-26.1 (SEQ ED NO: 99) k) DF 1-27.1 (SEQ ED NO: 100) 1) DF 1-28.1 (SEQ ID NO: 101) m) DF 1-28.2 (SEQ ID NO: 102) n) DF I-l (SEQ ID NO: 72); o) DP E-20 (SEQ ED NO: 50); p) DP E-20.1 (SEQ ID NO: 51) q) DP E-20.2 (SEQ ED NO: 52) r) DP E-20.3 (SEQ ED NO: 53) s) DP E-20.4 (SEQ ED NO: 54) t) DP E-20.5 (SEQ ED NO: 55) u) DP E 20.6 (SEQ ED NO: 56) v) " DP E-l (SEQ ED NO: 41); w) DP E-l.l (SEQ ED NO: 57); x) DP E-1.2 (SEQ ED NO: 58); y) DP E-2.1 (SEQ ED NO: 59); z) DP E-2.2 (SEQ ED NO: 60); a') DP E-2.3 (SEQ ED NO: 61); b') DP E-21 (SEQ ED NO: 62); c') DP E-22 (SEQ ED NO: 63); d') DP E-26 (SEQ ED NO: 64); e') DP E-26.1 (SEQ ED NO:65); f ) DP E-23 (SEQ ED NO: 66); g') DP E-23.1 (SEQ ED NO: 67); h') DP E-24 (SEQ ED NO: 68); i') DP E-25 (SEQ ED NO: 69); j') DP E-25.1 (SEQ ED NO: 70); k') DP E-25.2 (SEQ ED NO: 71);
I') DF E-l (SEQ ED NO: 103); m') DF E-2 (SEQ ED NO: 104); n') DF E-13.1 (SEQ ED NO: 105); 


 o') DF II-3.1 (SEQ ID NO: 106); p') DF II-4.5 (SEQ ID NO: 107); q') DF E-4.3 (SEQ ID NO: 108); r
*
) DF 11-15 (SEQ ED NO: 109); s") DF E-16 (SEQ ID NO: 110); t
*
) DF II- 17 (SEQ ID NO: 1 11); u') DF 11-18 (SEQ ID NO: 112); v') DF E-19 (SEQ ID NO: 113); w') DF E-19.1 (SEQ ID NO: 114); x') DF E-21 (SEQ ED NO: 115); and y') DF E-22 (SEQ ID NO: 116). wherein X
n
 are amino acid residues contiguous to the amino terminus of Y in the amino acid sequence of said protein allergen, wherein Z
τn
 are amino acid residues contiguous to d e carboxy terminus of Y in the amino acid sequence of said protein allergen, wherein n is 0-30 and wherein m is 0-30.
39. All or a portion of an isolated peptide of claim 38 wherein n=0 and m=0.
40. A portion of an isolated peptide of claim 38 wherein the portion comprises at least fifteen amino acid residues.
41. An isolated peptide of claim 38 wherein the peptide comprises up to 45 amino acids.
42. All or a portion of an isolated peptide of claim 38 which does not bind immunoglobulin E specific for a protein allergen of the genus Dermatophagoides in a substantial percentage of individuals sensitive to the protein allergen, or if binding of the peptide or portion thereof to said immunoglobulin E occurs, such binding does not result in release of mediators from mast cells or basophils in a substantial percentage of individuals sensitive to die protein allergen.
43. An isolated peptide of claim 38 which binds immunoglobulin E to a substantially lesser extent than the protein allergen from which the peptide is derived binds said immunoglobulin E. 


44. All or a portion of an isolated peptide of a protein allergen of the genus Dermatophagoides. said peptide or portion thereof comprising at least one T cell epitope of said protein allergen, said peptide comprising an amino acid sequence selected from die group consisting of: a) DFI-l (SEQ E NO: 72); b) DF 1-2.1 (SEQ ED NO: 73); c) DF 1-3 (SEQ ED NO: 74); d) DF 1-4 (SEQ ED NO: 75); e) DF I-ll (SEQ ED NO: 76); f) DF 1-12 (SEQ ED NO: 77); g) DF 1-5 (SEQ ED NO: 78); h) DF I-13 (SEQED NO: 79); i) DF 1-14 (SEQ ED NO: 80); j) DF 1-15 (SEQ ED NO: 81); k) DF 1-6 (SEQ ED NO: 82);
1) DF 1-7 (SEQ ED NO: 83); m) DF I-8.I (SEQ ED NO: 84); n) DFI-8 (SEQ ED NO: 85); o) DF 1-9 (SEQ ED NO: 86); p) DF 1-16 (SEQ ED NO: 87); q) DF 1-10 (SEQ ED NO: 88); r) DF 1-17 (SEQ ED NO: 89); s) DF 1-21.1 (SEQ ED NO: 90); t) DF 1-21.2 (SEQ ED NO: 91); u) DF 1-22.1 (SEQ ED NO: 92); v) DF I-22.2 (SEQ ED NO: 93); w) DF 1-22.4 (SEQ ED NO: 94); x) DF 1-23.1 (SEQ ED NO: 95); y) DF 1-23.2 (SEQ ED NO: 96); z) DF 1-25.1 (SEQ ED NO: 97); a') DF 1-25.2 (SEQ ED NO: 98); b') DF 1-26.1 (SEQ ED NO: 99); c') DF 1-27.1 (SEQ ED NO: 100); d') DF 1-28.1 (SEQ ED NO: 101); e') DF 1-28.2 (SEQ ED NO: 102); f ) DP E-20 (SEQ ED NO: 50); g)
r
 DP E-20.1 (SEQ ED NO: 51); 


 h DP E-20.2 (SEQ ID NO: 52) i DP II-20.3 (SEQ ID NO: 53) j DP E-20.4 (SEQ ID NO: 54) k DP E-20.5 (SEQ ID NO: 55)
I DP II 20.6 (SEQ ID NO: 56) m DP E-l (SEQ ID NO: 41); o DP E-2 (SEQ ID NO: 42); P DPE-3.1(SEQIDNO:43); q DP E-4 (SEQ ID NO: 44) r' DP II-5 (SEQ ID NO: 45) s DP E-6 (SEQ ID NO: 46) t' DP E-7 (SEQ ID NO: 47) u DP E-8 (SEQ ED NO: 48)
V DP E-9 (SEQ ID NO: 49) w DP E-1.1 (SEQ ED NO: 57)
X DPE-1.2(SEQIDNO:58) y DP E-2.1 (SEQ ID NO: 59) z' DP E-2.2 (SEQ ID NO: 60) a' DP E-2.3 (SEQ ED NO: 61) b DP E-21 (SEQ ID NO: 62) c' DP E-22 (SEQ ED NO: 63) d' DP E-26 (SEQ ED NO: 64) e' DPE-26.1(SEQEDNO:65); r DP E-23 (SEQ ID NO: 66); g' DPE-23.1(SEQEDNO:67); DP E-24 (SEQ ID NO: 68); DP E-25 (SEQ ID NO: 69);
J DPE-25.1(SEQEDNO:70); k" DP E-25.2 (SEQ ED NO: 71); 1" DF E-l (SEQ ID NO: 103); m DF II-2 (SEQ ID NO: 104); n" DF E-13.1 (SEQ ID NO: 105); o" DF II-3.1 (SEQ ID NO: 106) P" DF E-4.5 (SEQ ID NO: 107) q" DF E-4.3 (SEQ ED NO: 108) r' DFE-15(SEQIDNO:109); s DFE-16(SEQIDNO:110); 



 t") DF E-17 (SEQ ED NO: 111); u") DF E-18 (SEQ ID NO: 112); v") DF E-19 (SEQ ED NO: 113); w") DF E-19.1 (SEQ ED NO: 114); x") DF E-21 (SEQ ID NO: 115); and y") DF E-22 (SEQ ED NO: 116).
45. A portion of an isolated peptide of claim 44 which has a mean T cell stimulation index equivalent to or greater than the mean T cell stimulation index of said peptide as shown in Fig. 10, Fig. 15a and Fig 16a.
46. A portion of an isolated peptide of claim 44 wherein the portion comprises at least fifteen amino acid residues.
47. An isolated peptide of claim 44 wherein the peptide comprises up to 45 amino acids.
48. All or a portion of an isolated peptide of claim 44 which has minimal immunoglobulin E stimulating activity.
49. All or a portion of an isolated peptide of claim 44 which does not bind immunoglobulin E specific for a protein allergen of the genus Dermatophagoides in a substantial percentage of individuals sensitive to d e protein allergen or if binding of die peptide or portion tiiereof to said immunoglobulin E occurs, such binding does not result in release of mediators from mast cells or basophils in a substantial percentage of individuals sensitive to the protein allergen.
50. All or a portion of an isolated peptide of claim 44 which binds immunoglobulin E to a substantially lesser extent than the protein allergen from which the peptide is derived binds said immunoglobulin E.
51. All or a portion of an isolated peptide of claim 44 which modifies, in an individual sensitive to house dust mite to whom it is admimstered, me allergic response of the individual to a house dust mite allergen.
52. An isolated nucleic acid having a sequence encoding all or a 


 portion of a peptide of claim 44, or the functional equivalent of said nucleic acid sequence.
53. An isolated peptide which is immunologically cross-reactive with antibodies specific for all or a portion of a peptide of claim 44.
54. An isolated peptide which is immunologically cross-reactive with T cells reactive with all or a portion of a peptide of claim 44.
55. An isolated peptide of a protein allergen of the genus Dermatophagoides. said peptide selected from the group consisting of: a) DF I-l (SEQ ID NO: 72); b) DF 1-21.1 (SEQ ED NO: 90); c) DF I-22.1 (SEQ ED NO: 92); d) DF 1-25.1 (SEQ ID NO: 97); e) DF 1-23.1 (SEQ ID NO: 95); f) DF 1-9 (SEQ ID NO: 86); g) DF 1-21.2 (SEQ ID NO: 91); h) DP E-l (SEQ ED NO: 41); i) DP E-l.2 (SEQ ED NO: 58); j) DP E-22 (SEQ ED NO: 63); k) DP E-25.1 (SEQ ID NO: 70);
1) DP E-21 (SEQ ED NO: 62); m) DP E-25 (SEQ ED NO: 69); n) DP E-20.6 (SEQ ED NO: 56); o) DP E-20 (SEQ ID NO: 50); p) DF E-4.5 (SEQ ED NO: 107); q) DF E-2 (SEQ ED NO: 104); r) DF E-19.1 (SEQ ID NO: 114); s) DF E-17 (SEQ ED NO: l ll); t) DF E-15 (SEQ ID NO: 109). u) DP E-25.2 (SEQ ID NO: 71 ); and v) DF 1-22.2 (SEQ ID NO: 92)
56. A modified peptide or a modified portion of a peptide of claim 44. 


 57. A modifed peptide or a modified portion of a peptide of claim 56 selected from the group of peptides consisting of DP E-22.1 and DPE-22.2 as shown in Fig.28.
58. A modified peptide or modified portion of a peptide of claim 56 which does not bind immunoglobulin E specific for a protein allergen of the genus Dermatophagoides in a substantial percentage of individuals sensitive to the protein allergen, or if binding of d e peptide or portion thereof to said immunoglobulin E occurs, such binding does not result in release of mediators from mast cells or basophils in a substantial percentage of individuals sensitive to me protein allergen.
59. A modified peptide or a modified portion of a peptide of claim 56 which binds immunoglobulin E to a substantially lesser extent than the protein allergen from which die peptide is derived binds said immunoglobulin E.
60. A modified peptide or a modified portion of a peptide of claim 56 which modifies, in an individual sensitive to house dust mite to whom it is administered, the allergic response of the individual to a house dust mite allergen.
61. An isolated peptide of a protein allergen of the genus Dermatophagoides, said peptide selected from die group consisting of: a) DF I-l (SEQ ED NO: 72); b) DF.I-2.1 (SEQ ED NO: 73); c) DF I-3 (SEQED NO: 74); d) DF 1-4 (SEQ ED NO: 75); e) DF I-ll (SEQED NO: 76); f) DF 1-12 (SEQ ED NO: 77); g) DF 1-5 (SEQ ED NO: 78); h) DF 1-13 (SEQ ED NO: 79); i) DF 1-14 (SEQ ID NO: 80); j) DF 1-15 (SEQ ED NO: 81); k) DF 1-6 (SEQ ED NO: 82); 1) DF I-7 (SEQED NO: 83); m) DF 1-8.1 (SEQ ED NO: 84); 


 i) DP E-2.2 (SEQ ID NO: 60); a") DP E-2.3 (SEQ ID NO: 61); b") DP E-21 (SEQ ED NO: 62); c") DP E-22 (SEQ ED NO: 63); d") DP E-26 (SEQ ED NO: 64); e") DP E-26.1 (SEQ ED NO: 65); f ') DP E-23 (SEQ ED NO: 66); g") DP E-23.1 (SEQ ID NO: 67); h") DP E-24 (SEQ ED NO: 68); i") DP E-25 (SEQ ED NO: 69); j") DP E-25.1 (SEQ ED NO: 70); k") DP E-25.2 (SEQ ED NO: 71);
1") DF E-l (SEQ ED NO: 103); m") DF E-2 (SEQ ED NO: 104); n") DF E-13.1 (SEQ ED NO: 105); o") DF E-3.1 (SEQ ED NO: 106); p") DF E-4.5 (SEQ ED NO: 107); q") DF E-4.3 (SEQ ED NO: 108); r") DF E-15 (SEQ ID NO: 109); s") DF E-16 (SEQ ED NO: 110); t") DF E-17 (SEQ ED NO: 111); u") DF E-18 (SEQ ED NO: 112); v") DF E-19 (SEQ ED NO: 113); w") DF E-19.1 (SEQ ED NO: 114); x") DF E-21 (SEQ ED NO: 115); and y") DF E-22 (SEQ ED NO: 116).
62. A tiierapeutic composition comprising at least one isolated peptide of claim 1 and a pharmaceutically acceptable carrier or diluent.
63. A metiiod of treating sensitivity to house dust mite in an individual, comprising administering to d e individual a dierapeutically effective amount of the composition of claim 62.
64. A method of treating sensitivity to house dust mite in an individual, comprising administering simultaneously or sequentially to d e individual a dierapeutically effective amount of at least two different 


 compositions of claim 62.
65. A tiierapeutic composition comprising at least one isolated peptide of claim 18 and a pharmaceutically acceptable carrier or diluent.
66. A method of treating sensitivity to house dust mite in an individual, comprising administering to d e individual a dierapeutically effective amount of the composition of claim 65.
67. A therapeutic composition comprising at least one isolated peptide of claim 28 and a pharmaceutically acceptable carrier or diluent
68. A method of treating sensitivity to house dust mite in an individual, comprising administering to the individual a dierapeutically effective amount of die composition of claim 67.
69. A tiierapeutic composition comprising at least one isolated peptide of claim 34 and a pharmaceutically acceptable carrier or diluent.
70. A meti od of treating sensitivity to house dust mite in an individual, comprising administering to the individual a dierapeutically effective amount of the composition of claim 69.
71. A therapeutic composition comprising all or a portion of at least one isolated peptide of claim 38 and a pharmaceutically acceptable carrier or diluent.
72. A metiiod of treating sensitivity to house dust mite in an individual, comprising administering to d e individual a dierapeutically effective amount of the composition of claim 71.
73. A metiiod of treating sensitivity to house dust mite in an individual, comprising administering simultaneously or sequentially to the individual a therapeutically effective amount of at least two different compositions of claim 71. 


 74. A therapeutic composition comprising all or a portion of at least one isolated peptide of claim 44 and a pharmaceutically acceptable carrier or diluent
75. A method of treating sensitivity to house dust mite in an individual, comprising administering to die individual a dierapeutically effective amount of the composition of claim 74.
76. A therapeutic composition comprising at least one isolated peptide of claim 61 and a pharmaceutically acceptable carrier or diluent.
77. A metiiod of treating sensitivity to house dust mite in an individual, composing administering to me individual a dierapeutically effective amount of the composition of claim 76.
78. A method of detecting sensitivity to house dust mite in an individual, comprising combining a blood sample obtained from the individual witii at least one peptide of claim 1, under conditions appropriate for binding of blood components with the peptide, and determining the extent to which such binding occurs as indicative of sensitivity in the individual to house dust mite.
79. A metiiod of claim 78 wherein the extent to which binding occurs is determined by assessing T cell function, T cell proliferation or a combination thereof.
80. A method of detecting sensitivity to house dust mite in an individual, comprising combining a blood sample obtained from die individual with at least one peptide of claim 18, under conditions appropriate for binding of blood components with the peptide, and determining the extent to which such binding occurs as indicative of sensitivity in the individual to house dust mite.
81. A method of claim 80 wherein the extent to which binding occurs is determined by assessing T cell function, T cell proliferation or a combination thereof. 


82. A method of detecting sensitivity to house dust mite in an individual, comprising combining a blood sample obtained from the individual with all or a portion of at least one peptide of claim 38, under conditions appropriate for binding of blood components witii the peptide or portion d ereof, and determining the extent to which such binding occurs as indicative of sensitivity in the individual to house dust mite.
83. A method of claim 82 wherein the extent to which binding occurs is determined by assessing T cell function, T cell proliferation or a combination thereof.
84. A therapeutic composition comprising a pharmaceutically acceptable carrier or diluent and at least two peptides, said peptides each comprising at least one T cell epitope of a protein allergen of the genus Dermatophagoides . said peptides derived from the same or from different protein allergens of the genus Dermatophagoides.
85. A composition of claim 84 wherein said peptides are selected from the group consisting of: a) DP 1-21.1 (SEQ ID NO: 27); b) DP 1-21.2 (SEQ ID NO: 28); c) DP 1-22.1 (SEQ ID NO: 29); d) DP 1-22.2 (SEQ ED NO: 30); e) DP 1-22.3 (SEQ ED NO: 31); f) DP 1-22.4 (SEQ ID NO: 32); g) DP 1-23.1 (SEQ ED NO: 33); h) DP 1-23.2 (SEQ ID NO: 34); i) DP 1-25.1 (SEQ ED NO: 35); j) DP 1-25.2 (SEQ ED NO: 36); k) DP 1-26.1 (SEQ ID NO: 37); 1) DP 1-27.1 (SEQ ED NO: 38); m) DP 1-28.1 (SEQ ID NO: 39); n) DP 1-28.2 (SEQ ID NO: 40); o) DP I-l (SEQ ID NO: 9); p) DF I-l (SEQ ED NO: 72); q) DF 1-21.1 (SEQ ID NO: 90); r) DF 1-21.2 (SEQ ID NO: 91); 


 d") DF II-3.1 (SEQ ID NO: 106); e") DF E-4.5 (SEQ ID NO: 107); f ') DF E-4.3 (SEQ ID NO: 108); g") DF II-15 (SEQ ID NO: 109); h") DF E-16 (SEQ ID NO: 110); i") DF II- 17 (SEQ ID NO: 111); j") DF E-18 (SEQ ID NO: 112); k") DF E-19 (SEQ ID NO: 113);
1") DF E-19.1 (SEQ ID NO: 114) m") DF E-21 (SEQ ID NO: 115); and n") DF E-22 (SEQ ID NO: 116), wherein said composition comprises a sufficient percentage of the T cell epitopes of at least one protein allergen such that upon administration of the composition to an individual sensitive to a house dust mite allergen, T cells of the individual are tolerized to said at least one protein allergen.
86. A composition of claim 85 wherein said peptides are selected from the group consisting of : a)DP 1-21.2 (SEQ ID NO:27); b)DP 1-23.1 (SEQ ID NO:33); c)DP 1-26.1 (SEQ ID NO:37); d)DP E-20.6(SEQ ED NO:56); e)DP E-22 (SEQ ED NO:63); f)DP E-25.2 (SEQ ED NO:71); and g)DF 1-22.2 (SEQ ED NO:93).
87. A composition of claim 84 comprising a combination of peptides selected from die group consisting of: a) DP 1-22.1 (SEQ ID NO: 29) and DP 1-25.1 (SEQ ID NO: 35); b) DP 1-21.1 (SEQ ID NO: 27) and DP 1-25.2 (SEQ ID NO: 36); c) DP 1-22.1 (SEQ ID NO: 29) and DP I- 1 (SEQ ID NO: 9); d) DP 1-21.1 (SEQ ED NO: 27), DP 1-22.1 (SEQ ED NO: 29), and DP 1-25.2 (SEQ ED 


 NO: 36); e) DP 1-21.2 (SEQ ID NO: 28), DP 1-22.1 (SEQ ID NO: 29), and DP 1-23.1 (SEQ ID NO: 39); f) DP I-l (SEQ TD NO: 9), DP 1-22.1 (SEQ ID NO: 29), and DP 1-23.1 (SEQ ED NO: 33); g) DP I-l (SEQ ED NO: 9), DP 1-22.1 (SEQ ED NO: 29), and DP 1-25.2 (SEQ ID NO: 36); h) DP 1-21.1 (SEQ ED NO: 27), DP 1-22.1
(SEQ ED NO: 29), DP 1-23.1 (SEQ ED NO:
33), and DP 1-25.2 (SEQ ID NO: 36); i) DP 1-21.2 (SEQ ED NO: 28), DP 1-22.1
(SEQ ED NO: 29), and DP 1-25.2 (SEQ ED
NO: 36); j) DP 1-21.2 (SEQ ED NO: 27), DP 1-22.1
(SEQ ED NO: 29), DP 1-25.2 (SEQ ED NO:
36), and DP 1-26.1 (SEQ ED NO: 37); k) DF 1-21.2 (SEQ ED NO: 91) and DF 1-22.1
(SEQED NO: 92);
1) DF 1-21.1 (SEQ ED NO: 90), DF 1-22.1
(SEQ ED NO: 92), and DF 1-25.1 (SEQ ID
NO: 97); m) DF 1-21.2 (SEQ ED NO: 91), DF 1-22.1
(SEQ ED NO: 92), and DF 1-25.1 (SEQ ID
NO: 97); n) DF I-l (SEQ ED NO: 72) and DF 1-22.1
(SEQED NO: 92); o) DF I-l (SEQ ED NO: 72), DF 1-22.1 (SEQ
ED NO: 92), and DF 1-25.1 (SEQ D NO: 97); p) DF 1-22.1 (SEQ ID NO: 29), and DF 1-25.1
(SEQ ED NO: 35); q) DF 1-21.1 (SEQ ED NO: 90), DF 1-22.1
(SEQ ED NO: 92), and DF 1-23.1 (SEQ ED
NO: 95); r) DP 1-21.1 (SEQ ED NO: 27), and DF 1-22.1
(SEQ ED NO: 92); s) DP I-l (SEQ ED NO: 9), DP 1-23.1 (SEQ ED 


 NO: 33), DP 1-25.1 (SEQ ID NO: 35), and
DF I-l (SEQ ID NO: 72); t) DP I- 1 (SEQ TD NO: 9), DP 1-25.1 (SEQ ID
NO: 35), DP 1-23.1 (SEQ ID NO: 33), and
DF 1-21.2 (SEQ ID NO: 91); u) DP I-l (SEQ ED NO: 9), DP 1-25.1 (SEQ ID
NO: 35), DP 1-23.1 (SEQ ID NO: 33), and
DF 1-21.1 (SEQ ID NO: 90); v) DP E-22 (SEQ ID NO: 63), and DP E-25.2
(SEQ ID NO: 71); w) DP E-22 (SEQ ED NO: 63), DP E-25.2
(SEQ ID NO: 71), and DP 1-21.1 (SEQ ID
NO: 27) and DP 1-22.1 (SEQ ED NO: 29); x) DP E-22 (SEQ ED NO: 63), DP E-25.2
(SEQ ED NO: 71), DP E-20.6 (SEQ ED NO:
56), DP 1-22.1 (SEQ ED NO: 29), DP 1-21.1
(SEQ ED NO: 27), and DP 1-23.1 (SEQ ID
NO: 33); y) DP E-22 (SEQ ED NO: 63), DP E-25.2
(SEQ ED NO: 71), DP E-20.6 (SEQ ED NO:
56), DP 1-21.1 (SEQ ED NO: 27), DP 1-22.1
(SEQ ID NO: 29), and DP 1-25.2 (SEQ ID
NO: 36); z) DP E-22 (SEQ ED NO: 63), DP E-25.2
(SEQ ID NO: 71), DP 1-21.1 (SEQ ED NO:
27), DP 1-22.1 (SEQ ED NO: 29), and DP I-
25.2 (SEQ ED NO: 36); a') DP E-22 (SEQ ED NO: 63), DP E-25.2
(SEQ ID NO: 71), DP 1-21.1 (SEQ ED NO:
27), DP 1-22.1 (SEQ ED NO: 29), and DP I-
23.1 (SEQ ID NO: 33); b
*
) DP E-22 (SEQ ID NO: 63), DP E-25.2
(SEQ ED NO: 71), DP I-l (SEQ ID NO: 9), and DP 1-22.1 (SEQ ID NO: 29); c') DF E-4.5 (SEQ ID NO: 107) and DF E-2
(SEQ ED NO: 104); d') DF II-4.5 (SEQ ID NO: 107) and DF E-19.1 


 (SEQ ED NO: 114); e
*
) DF E-4.5 (SEQ ID NO: 107), DF E-2 (SEQ
ED NO: 104), and DF E-19.1 (SEQ ID NO: 114); f ) DF E-4.5 (SEQ ED NO: 107), DF E-2 (SEQ
ID NO: 104), and DF E-9 (SEQ ED NO: 86); g') DF E-4.5 (SEQ ID NO: 107); and DF 1-21.1
(SEQ ED NO: 90); h") DF E-4.5 (SEQ ID NO: 107), DP E-22
(SEQ ED NO: 63), and DP E-25.2 (SEQ ID
NO: 71); and i
l
) DF E-4.5 (SEQ ED NO: 107), DF E-2 (SEQ
ED NO: 104), and DP E-22 (SEQ ED NO: 63).
88. A composition of claim 85 comprising the following combination of peptides: DP I-21.2(SEQ ED NO:27),DP I-23.1(SEQ ED NO:33), DP I- 26.1 (SEQ TD NO.-37), DP E-20.6(SEQ ED NO:56), DP E-22(SEQ ED NO:63), DP E-25.2(SEQ ED NO:71), and DF I-22.2(SEQ ED NO:93).
89. A method of treating sensitivity to house dust mite in an individual, comprising administering to the individual a therapeutically effective amount of the composition of claim 84.
90. A method of treating sensitivity to house dust mite in an individual, comprising administering to die individual a dierapeutically effective amount of the composition of claim 85.
91. A method of treating sensitivity to house dust mite in an individual, comprising administering to the individual a dierapeutically effective amount of the composition of claim 86.
92. A method of treating sensitivity to house dust mite in an individual, comprising administering to the individual a therapeutically effective amount of the composition of claim 88.
93. A therapeutic composition comprising at least one peptide of at least one protein allergen of the genus Dermatophagoides and a pharmaceutically acceptable carrier or diluent, said composition comprising a 


 sufficient percentage of the T cell epitopes of said at least one protein allergen such that upon administration of the composition to an individual sensitive to a house dust mite allergen, T cells of the individual are tolerized to said at least one protein allergen.
94. A therapeutic composition of claim 93 wherein said protein allergen is selected from the group consisting of: Der p I; Der f I; Der p II; and Deri E.
95. A method of treating sensitivity to house dust mite in an individual, comprising administering to me individual a therapeutically effective amount of a composition of claim 93.
96. A modified peptide of claim 21 or 56 wherein at least one of the amino acid residues which bind d e MHC protein complex but is not essential for such binding is substituted.
97. A modified peptide of claim 96 wherein said amino acid residues are substituted with amino acids selected from the group consisting of alanine, glutamic acid, and a methyl amino acid.
98. The modified peptide of claim 96 wherein at least one of the amino acid residues which is essential for binding to die MHC protein complex is substituted witii a conservative amino acid residue.
99. A modified peptide of claim 21 or 56 wherein at least one of die amino acid residues which binds to die T cell receptor, but is not essential for such binding is substituted. 

</CLAIMS>
</TEXT>
</DOC>
